<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02882451</url>
  </required_header>
  <id_info>
    <org_study_id>ERCP-02</org_study_id>
    <nct_id>NCT02882451</nct_id>
  </id_info>
  <brief_title>Impact of Pinaverium Bromide on Bile Duct and Pancreatic Duct Cannulation During Endoscopic Retrograde Cholangiopancreatography</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pinaverium bromide can be used to treat symptoms related to irritable bowel syndrome (IBS)
      and functional disorders of the biliary tract. In this study, pinaverium bromide was compared
      with Vitamin C for the facilitation of bile duct and pancreatic duct cannulation in patients.
      The primary outcome was successful deep bile duct cannulation and pancreatic duct canulation.
      The second outcome was the major papillary orifice,bile juice flow from the papilla, time to
      achieve deep bile duct cannulation, fluoroscopy time for deep bile duct cannulation,the
      appearance of the major and minor papillary orifice, pancreatic juice flow from the papilla,
      time to achieve deep pancreatic duct cannulation, and fluoroscopy time for deep pancreatic
      duct cannulation in the pinaverium bromide group versus Vitamin C group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cannulation time for deep bile duct cannulation and pancreatic duct cannulation</measure>
    <time_frame>2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>bile juice flow from the major papilla and pancreatic juice flow from the major papilla</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>appearance of the major papillary orifice</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bile Duct Diseases</condition>
  <arm_group>
    <arm_group_label>pinaverium bromide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>take 50 mg pinaverium bromide three times a day 1 days before and then 100 mg 1 hour before the examination orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>take 50 mg Vitamin C three times a day 1 days before and then 100 mg 1 hour before the examination orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>pinaverium bromide</intervention_name>
    <arm_group_label>pinaverium bromide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <arm_group_label>Vitamin C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. those with intact native papilla,

          2. who underwent endoscopic retrograde choledochopancreatography for bile duct,

          3. age≥18 years, ≤80years, and

          4. agreement to participate in the study.

        Exclusion Criteria:

          1. a previous sphincterotomy,

          2. previous attempted or unsuccessful endoscopic retrograde choledochopancreatography
             with papillary manipulation,

          3. indwelling biliary or pancreatic stent(s),

          4. active acute pancreatitis,

          5. active acute pancreatitis

          6. altered/postsurgical anatomy,

          7. history of gastroparesis,

          8. endoscopic retrograde choledochopancreatography for sphincter of Oddi's sphincter(SO)
             manometry,

          9. known tumor of the major duodenal papilla, and

         10. patients with any medication probably affecting SO motility
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shu-Ling Wang, M.D</last_name>
    <phone>021-81873241</phone>
    <email>wangshuling0000@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu Bai, M.D</last_name>
    <phone>021-81873241</phone>
    <email>baiyu1998@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Changhai Hospital, Second Military Medical University</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhaoshen Li, MD</last_name>
      <phone>86-21-81873241</phone>
      <email>zhaoshenlismmu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>zhaoshen Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2016</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Zhaoshen Li</investigator_full_name>
    <investigator_title>Head of Digestive Endoscopy Center</investigator_title>
  </responsible_party>
  <keyword>bile duct</keyword>
  <keyword>endoscopic retrograde cholangiopancreatography</keyword>
  <keyword>pinaverium bromide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bile Duct Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Pinaverium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

